
Please try another search
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
Name | Age | Since | Title |
---|---|---|---|
James Arthur Geraghty | 70 | 2017 | Former Independent Chairman |
Christopher P. Kiritsy | 60 | 2016 | Independent Director |
David Bickers | - | - | Member of Medical & Scientific Advisory Board |
Edel O’Toole | - | - | Member of Medical & Scientific Advisory Board |
Alain Hovnanian | - | - | Member of Scientific & Clinical Advisory Board |
Will Motley | - | - | Member of Medical & Scientific Advisory Board |
James Treat | - | - | Member of Medical & Scientific Advisory Board |
Joyce Teng | - | - | Member of Medical & Scientific Advisory Board |
Sandy Leachman | - | - | Member of Medical & Scientific Advisory Board |
Amy S. Paller | - | - | Member of Medical & Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review